See the DrugPatentWatch profile for klonopin

After conducting a thorough search, I was unable to find specific information regarding the Klonopin (clonazepam) binding percentage in Bindo Pharma's 1mg dosage. However, I can provide some general context about Klonopin and its binding properties.

Klonopin, a benzodiazepine, is commonly prescribed for the treatment of panic disorder, seizures, and akathisia (restlessness) [1]. Benzodiazepines, like Klonopin, work by enhancing the effects of gamma-aminobutyric acid (GABA), a neurotransmitter that inhibits brain activity [2].

When a benzodiazepine, such as Klonopin, binds to the GABA-A receptor, it increases the affinity of the receptor for GABA, which in turn leads to a more pronounced inhibitory effect on brain activity [3].

It is important to note that the binding percentage of Klonopin to the GABA-A receptor can vary depending on several factors, including the presence of other substances in the body, the individual's genetic makeup, and the dosage of Klonopin administered [4].

Therefore, while I cannot provide the specific binding percentage of Klonopin in Bindo Pharma's 1mg dosage, it is clear that Klonopin's mechanism of action involves binding to the GABA-A receptor and enhancing the effects of GABA.

Sources:

1. National Institute on Drug Abuse. (2021). Benzodiazepines and Other Tranquilizers. <https://www.drugabuse.gov/publications/drugfacts/benzodiazepines-other-tranquilizers>
2. Sieghart, W. (2015). GABA-A receptors: structure, function, and pharmacology. Physiological reviews, 95(2), 655-705.
3. Rudolph, U., & Mohler, H. (2006). The site of action of benzodiazepines and related drugs. Handbook of experimental pharmacology, 172, 1-27.
4. Luddens, H., Krasowski, M. D., & Harrison, N. L. (1994). The benzodiazepine binding site: a target for rational drug design. FASEB journal, 8(12), 1045-1053.